ROQ vs. GENF, BSFA, VAL, IXI, OCTP, FAB, APTA, IMM, BVX, and EVG
Should you be buying Roquefort Therapeutics stock or one of its competitors? The main competitors of Roquefort Therapeutics include Genflow Biosciences (GENF), BSF Enterprise (BSFA), ValiRx (VAL), IXICO (IXI), Oxford Cannabinoid Technologies (OCTP), Fusion Antibodies (FAB), Aptamer Group (APTA), ImmuPharma (IMM), BiVictriX Therapeutics (BVX), and Evgen Pharma (EVG). These companies are all part of the "biotechnology" industry.
Roquefort Therapeutics (LON:ROQ) and Genflow Biosciences (LON:GENF) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, community ranking, valuation, earnings and risk.
Roquefort Therapeutics' return on equity of -33.20% beat Genflow Biosciences' return on equity.
Roquefort Therapeutics has a beta of -0.03, meaning that its stock price is 103% less volatile than the S&P 500. Comparatively, Genflow Biosciences has a beta of 2.47, meaning that its stock price is 147% more volatile than the S&P 500.
In the previous week, Roquefort Therapeutics had 1 more articles in the media than Genflow Biosciences. MarketBeat recorded 1 mentions for Roquefort Therapeutics and 0 mentions for Genflow Biosciences. Roquefort Therapeutics' average media sentiment score of 0.00 equaled Genflow Biosciences'average media sentiment score.
Roquefort Therapeutics and Genflow Biosciences both received 0 outperform votes by MarketBeat users.
1.7% of Roquefort Therapeutics shares are owned by institutional investors. Comparatively, 9.2% of Genflow Biosciences shares are owned by institutional investors. 71.0% of Roquefort Therapeutics shares are owned by insiders. Comparatively, 63.7% of Genflow Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Genflow Biosciences has lower revenue, but higher earnings than Roquefort Therapeutics.
Summary
Roquefort Therapeutics beats Genflow Biosciences on 5 of the 9 factors compared between the two stocks.
Get Roquefort Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ROQ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ROQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Roquefort Therapeutics Competitors List
Related Companies and Tools
